Seizalam (Midazolam)

Generic Name

Midazolam

Brand Names

Seizalam, Nayzilam

FDA approval date: June 20, 2000

Classification: Benzodiazepine

Form: Injection, Spray, Syrup

What is Seizalam (Midazolam)?

Midazolam HCl Syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia. Midazolam HCl syrup is intended for use in monitored settings only and not for chronic or home use. WARNINGS MIDAZOLAM HCL SYRUP MUST BE USED AS SPECIFIED IN THE LABEL. Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours. CLINICAL PHARMACOLOGY.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Phase 1 Study to Further Investigate the Pharmacokinetics, Safety and Tolerability, Food Effect and Drug-Drug Interaction of LY4268989 (MORF-057) in Healthy Participants

Enrollment Status: Recruiting

Publish Date: October 09, 2025

Intervention Type: Drug

Study Phase: Phase 1

Summary: The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants

BUCCOLAM OROMUCOSAL SOLUTION - Special Drug Use Surveillance

Enrollment Status: Recruiting

Publish Date: October 06, 2025

Intervention Type: Drug

Summary: This study is a survey in Japan of midazolam oromucosal solution used to treat people with status epilepticus. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from midazolam oromucosal solution and to check if midazola...

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

Enrollment Status: Recruiting

Publish Date: October 03, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerability, PK and pharmacodynamics of MT-4561 and determining the Maximum Tolerated Dose (MTD) using the ...

View All Clinical Trials